ROSWELL PARK CANCER INSTITUTE

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Fludarabine Phosphate, Melphalan, and Low-Dose Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies

Phase 2

Completed

Conditions: Accelerated Phase Chronic Myelogenous Leukemia
Adult Acute Myeloid Leukemia in Remission
Childhood Acute Myeloid Leukemia in Remission
Childhood Chronic Myelogenous Leukemia
Childhood Grade III Lymphomatoid Granulomatosis
Adult Acute Lymphoblastic Leukemia in Remission
Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities
Adult Acute Myeloid Leukemia With Del(5q)
Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)
Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)

Interventions: Drug: fludarabine phosphate
Drug: melphalan
Radiation: total-body irradiation
Drug: tacrolimus
Drug: mycophenolate mofetil
Drug: methotrexate
Other: laboratory biomarker analysis
Procedure: allogeneic hematopoietic stem cell transplantation
Procedure: peripheral blood stem cell transplantation

First Posted Date: 2012-02-09

Last Posted Date: 2019-09-24

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 94

Registration Number: NCT01529827

Locations: 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States

Ofatumumab in Combination With Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine Sulfate, and Dexamethasone Alternating With Ofatumumab in Combination With Cytarabine and Methotrexate in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma

Phase 2

Completed

Conditions: Stage I Mantle Cell Lymphoma
Stage II Contiguous Mantle Cell Lymphoma
Stage II Non-Contiguous Mantle Cell Lymphoma
Stage III Mantle Cell Lymphoma
Stage IV Mantle Cell Lymphoma

Interventions: Procedure: Autologous Hematopoietic Stem Cell Transplantation
Drug: Cyclophosphamide
Drug: Cytarabine
Drug: Dexamethasone
Drug: Doxorubicin Hydrochloride
Other: Laboratory Biomarker Analysis
Drug: Methotrexate
Biological: Ofatumumab
Drug: Vincristine Sulfate

First Posted Date: 2012-02-06

Last Posted Date: 2024-02-07

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 37

Registration Number: NCT01527149

Locations: 🇺🇸
Vanderbilt University/Ingram Cancer Center, Nashville, Tennessee, United States
🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States

Entolimod in Treating Patients With Locally Advanced or Metastatic Solid Tumors That Cannot Be Removed By Surgery

Phase 1

Completed

Conditions: Unspecified Adult Solid Tumor, Protocol Specific

Interventions: Drug: entolimod
Other: pharmacological study
Other: laboratory biomarker analysis

First Posted Date: 2012-02-06

Last Posted Date: 2022-07-22

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 25

Registration Number: NCT01527136

Locations: 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States

Vaccine Therapy With or Without Sirolimus in Treating Patients With NY-ESO-1 Expressing Solid Tumors

Phase 1

Completed

Conditions: Recurrent Esophageal Carcinoma
Anaplastic Astrocytoma
Anaplastic Oligoastrocytoma
Anaplastic Oligodendroglioma
Estrogen Receptor Negative
Estrogen Receptor Positive
Glioblastoma
Hormone-Resistant Prostate Cancer
Metastatic Prostate Carcinoma
Metastatic Renal Cell Cancer

Interventions: Biological: DEC-205/NY-ESO-1 Fusion Protein CDX-1401
Other: Laboratory Biomarker Analysis
Other: Pharmacological Study
Drug: Sirolimus

First Posted Date: 2012-02-01

Last Posted Date: 2016-10-04

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 18

Registration Number: NCT01522820

Locations: 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States

Cholecalciferol in Treating Patients With Acute Myeloid Leukemia Undergoing Intensive Induction Chemotherapy

Phase 2

Terminated

Conditions: Adult Acute Monoblastic Leukemia (M5a)
Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities
Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)
Adult Acute Myelomonocytic Leukemia (M4)
Adult Acute Myeloblastic Leukemia Without Maturation (M1)
Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)
Adult Erythroleukemia (M6a)
Adult Pure Erythroid Leukemia (M6b)
Untreated Adult Acute Myeloid Leukemia
Adult Acute Myeloblastic Leukemia With Maturation (M2)

Interventions: Dietary Supplement: cholecalciferol
Other: pharmacological study
Other: laboratory biomarker analysis

First Posted Date: 2012-01-31

Last Posted Date: 2015-06-19

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 4

Registration Number: NCT01521936

Locations: 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States

Dovitinib Lactate, Gemcitabine Hydrochloride, and Capecitabine in Treating Patients With Advanced or Metastatic Solid Tumors, Pancreatic Cancer and Biliary Cancers

Phase 1

Completed

Conditions: Adenocarcinoma of the Pancreas
Stage III Pancreatic Cancer
Unspecified Adult Solid Tumor, Protocol Specific
Stage IV Pancreatic Cancer

Interventions: Drug: dovitinib lactate
Drug: gemcitabine hydrochloride
Drug: capecitabine
Other: laboratory biomarker analysis
Other: enzyme-linked immunosorbent assay
Other: pharmacological study

First Posted Date: 2011-12-22

Last Posted Date: 2022-07-22

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 26

Registration Number: NCT01497392

Locations: 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States

Photodynamic Therapy Using Methyl-5-Aminolevulinate Hydrochloride Cream in Determining Pain Threshold in Patients With Skin Cancer

Phase 1

Completed

Conditions: Basal Cell Carcinoma of the Skin
Pain
Recurrent Skin Cancer

Interventions: Drug: methyl-5-aminolevulinate hydrochloride cream
Procedure: laser therapy
Drug: photodynamic therapy

First Posted Date: 2011-02-09

Last Posted Date: 2014-09-29

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 21

Registration Number: NCT01292668

Locations: 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States

Edible Hepatitis B Vaccine Therapy in Healthy Participants Who Have Undergone Previous Vaccination

Not Applicable

Withdrawn

Conditions: Healthy, no Evidence of Disease

Interventions: Biological: hepatitis B antigen peptide
Other: placebo
Other: immunoenzyme technique

First Posted Date: 2011-02-09

Last Posted Date: 2022-10-03

Lead Sponsor: Roswell Park Cancer Institute

Registration Number: NCT01292421

Azadirachta Indica in Treating Patients With Chronic Lymphocytic Leukemia

Phase 1

Withdrawn

Conditions: Refractory Chronic Lymphocytic Leukemia
Stage II Chronic Lymphocytic Leukemia
Stage III Chronic Lymphocytic Leukemia
Stage IV Chronic Lymphocytic Leukemia

Interventions: Other: laboratory biomarker analysis
Genetic: western blotting
Genetic: gene expression analysis
Other: pharmacological study
Other: flow cytometry
Genetic: fluorescence in situ hybridization
Biological: azadirachta indica
Genetic: reverse transcriptase-polymerase chain reaction

First Posted Date: 2010-12-01

Last Posted Date: 2014-01-13

Lead Sponsor: Roswell Park Cancer Institute

Registration Number: NCT01251250

Vaccine Therapy and Sargramostim in Treating Patients With Malignant Glioma

Phase 1

Completed

Conditions: Giant Cell Glioblastoma
Gliosarcoma
Anaplastic Oligoastrocytoma
Glioblastoma
Anaplastic Oligodendroglioma
Anaplastic Astrocytoma
Mixed Glioma
Recurrent Brain Neoplasm

Interventions: Other: Laboratory Biomarker Analysis
Drug: Montanide ISA-51/Survivin Peptide Vaccine
Biological: Sargramostim

First Posted Date: 2010-11-30

Last Posted Date: 2017-02-27

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 9

Registration Number: NCT01250470

Locations: 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy